At the heart of PlaqueTec’s groundbreaking precision medicine strategy for coronary artery disease lies BioCarta – an exclusive, meticulously curated bioinformatics platform. BioCarta correlates in vivo biomarkers localizing at the disease site with a diverse array of circulating markers, OCT images, and genotypes. This invaluable resource empowers PlaqueTec to identify diagnostic signals and tailor targeted interventions to revolutionize patient care. BioCarta is powered by PlaqueTec’s novel intracoronary blood sampling technology, the Liquid Biopsy System. PlaqueTec’s commitment to conducting extensive trials across varied patient demographics is constantly broadening and enhancing BioCarta, shaping a future where CAD management is not only precise but also profoundly impactful.